John F. DiJoseph

2.5k citations

45 papers · 1.5k indexed · h-index 24

Oncology top 5%
Radiology, Nuclear Medicine and Imaging top 5%
Molecular Biology
Pathology and Forensic Medicine top 5%
Public Health, Environmental and Occupational Health top 10%

Co-authors: Maureen Dougher Nitin K. Damle Douglas Armellino Erwin R. Boghaert Philip R. Hamann Arthur Kunz Kiran Khandke Gisela Mir
Topics: Protease and Inhibitor Mechanisms (11 papers)Monoclonal and Polyclonal Antibodies Research (11 papers)Peptidase Inhibition and Analysis (9 papers)
Cited by: Transplantation Oncology Radiology, Nuclear Medicine and Imaging
Journals: Blood Gastroenterology Cancer Research
Partner nations: United States Canada United Kingdom

In The Last Decade

John F. DiJoseph

45 papers receiving 1.4k citations

Peers

Countries citing papers authored by John F. DiJoseph

Since Specialization

Citations

This map shows the geographic impact of John F. DiJoseph's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. DiJoseph with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. DiJoseph more than expected).

Fields of papers citing papers by John F. DiJoseph

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. DiJoseph. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. DiJoseph. The network helps show where John F. DiJoseph may publish in the future.

Co-authorship network of co-authors of John F. DiJoseph

This figure shows the co-authorship network connecting the top 25 collaborators of John F. DiJoseph. A scholar is included among the top collaborators of John F. DiJoseph based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John F. DiJoseph. John F. DiJoseph is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells 2012 ·Molecular Cancer Therapeutics ·Puja Sapra,Marc Damelin,John F. DiJoseph,Kimberly Marquette,Kenneth G. Geles,Jonathon Golas,Maureen Dougher,(unknown),Andreas Giannakou,Kiran Khandke,Russell G. Dushin,Elana Ernstoff,Judy Lucas,Mauricio Leal,(unknown),Christopher J. O’Donnell,Lioudmila Tchistiakova,Robert T. Abraham,Hans‐Peter Gerber	51
2	Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP 2010 ·Cancer Chemotherapy and Pharmacology ·John F. DiJoseph,Maureen Dougher,Deborah Y. Evans,Bin‐Bing S. Zhou,Nitin K. Damle	37
3	Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia 2007 ·Leukemia ·John F. DiJoseph,Maureen Dougher,Douglas Armellino,Deborah Y. Evans,Nitin K. Damle	96
4	Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma 2006 ·Clinical Cancer Research ·John F. DiJoseph,Maureen Dougher,(unknown),Douglas Armellino,Erwin R. Boghaert,Philip R. Hamann,Justin Moran,Nitin K. Damle	103
5	CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab 2006 ·Cancer Immunology Immunotherapy ·John F. DiJoseph,Maureen Dougher,Douglas Armellino,(unknown),Arthur Kunz,Erwin R. Boghaert,Philip R. Hamann,Nitin K. Damle	42
6	Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22 2004 ·Cancer Immunology Immunotherapy ·John F. DiJoseph,Andrew G. Popplewell,Simon Tickle,Heather M. Ladyman,Alastair D. G. Lawson,Arthur Kunz,Kiran Khandke,Douglas Armellino,Erwin R. Boghaert,Philip R. Hamann,K Zinkewich-Péotti,Sue Stephens,Neil Weir,Nitin K. Damle	55
7	Synthesis and Structure−Activity Relationships of 4-alkynyloxy Phenyl Sulfanyl, Sulfinyl, and Sulfonyl Alkyl Hydroxamates as Tumor Necrosis Factor-α Converting Enzyme and Matrix Metalloproteinase Inhibitors 2004 ·Journal of Medicinal Chemistry ·Aranapakam M. Venkatesan,(unknown),G Grosu,(unknown),Arie Zask,Jeremy I. Levin,John W. Ellingboe,Jerauld S. Skotnicki,John F. DiJoseph,Amy Sung,Guixian Jin,Weixin Xu,Diane Joseph‐McCarthy,D. Barone	35
8	Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·Arie Zask,Ying Gu,J. Donald Albright,Xinling Du,Michael E. Hogan,Jeremy I. Levin,(unknown),Loran M. Killar,Anita Sung,John F. DiJoseph,Michele A. Sharr,Catherine Roth,Stacey Skala,Guofeng Jin,Rebecca Cowling,K M Mohler,D. Barone,Roy A. Black,Carl J. March,J.S. Skotnicki	26
9	The discovery of anthranilic acid-based mmp inhibitors. Part 3: incorporation of basic amines 2001 ·Bioorganic & Medicinal Chemistry Letters ·Jeremy I. Levin,(unknown),(unknown),Frances C. Nelson,(unknown),John F. DiJoseph,Loran M. Killar,Stacey Skala,Anita Sung,Michele A. Sharr,Catherine Roth,Guofeng Jin,Rebecca Cowling,Li Di,(unknown),(unknown),Carl J. March,K M Mohler,Roy A. Black,Jerauld S. Skotnicki	30
10	Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases 2001 ·Bioorganic & Medicinal Chemistry Letters ·Jeremy I. Levin,Yansong Gu,Frances C. Nelson,Arie Zask,John F. DiJoseph,Michele A. Sharr,Amy Sung,Guixian Jin,Rebecca Cowling,Pranab K. Chanda,Scott Cosmi,Chu-Lai Hsiao,Wade Edris,James E. Wilhelm,Loran M. Killar,Jerauld S. Skotnicki	16
11	The synthesis and biological activity of a novel series of diazepine MMP inhibitors 1998 ·Bioorganic & Medicinal Chemistry Letters ·Jeremy I. Levin,John F. DiJoseph,Loran M. Killar,Amy Sung,Thomas S. Walter,Michele A. Sharr,Catherine Roth,Jerauld S. Skotnicki,J. Donald Albright	27
12	Malonyl α-mercaptoketones and α-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors 1998 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),(unknown),David C.H. Harris,(unknown),Reza Mortezaei,(unknown),Lihong Shi,(unknown),Yongwen Wang,Marc Navre,Dinesh V. Patel,Michele A. Sharr,John F. DiJoseph,Loran M. Killar,(unknown),Jeremy I. Levin,Jerauld S. Skotnicki	19
13	THERAPEUTIC BLOOD LEVELS OF SIROLIMUS (RAPAMYCIN) IN THE ALLOGRAFTED RAT 1996 ·Transplantation ·John F. DiJoseph,Eric Fluhler,(unknown),Michele A. Sharr,Suren N. Sehgal	33
14	Renal effects of rapamycin in the spontaneously hypertensive rat 1994 ·Transplant International ·John F. DiJoseph,Michael J. Mihatsch,Suren N. Sehgal	27
15	THE EFFECT OF RAPAMYCIN ON KIDNEY FUNCTION IN THE SPRAGUE-DAWLEY RAT 1992 ·Transplantation ·John F. DiJoseph,(unknown),Jennifer Y. Chang	88
16	Rapid induction of early osteoarthritic-like lesions in the rabbit knee by continuous intra-articular infusion of mammalian collagenase or interleukin-1 1991 ·Inflammation Research ·(unknown),C. P. Eng,John F. DiJoseph,Christine A. Wells,John Ward,Robert Caccese,(unknown)	9
17	Inhibition of interleukin-1 (IL-1) induced neutral proteases from rabbit articular chondrocytes by WY-46,135 and WY-48,989 1991 ·Inflammation Research ·Robert Caccese,John F. DiJoseph,Jerauld S. Skotnicki,(unknown),Laurel M. Adams	14
18	N-Phenyl-2-pyridinecarbothioamides as gastric mucosal protectants 1990 ·Journal of Medicinal Chemistry ·William A. Kinney,(unknown),Ralf Blank,Christopher A. Demerson,(unknown),(unknown),Gisela Mir,(unknown),John F. DiJoseph,(unknown)	17
19	Mucosal Protective Activity of Activated Aluminum Complex 1990 ·Digestion ·John F. DiJoseph,(unknown),(unknown),(unknown)	4
20	Cytoprotective and antiulcer activities of the antacid magaldrate in the rat. 1989 ·PubMed ·(unknown),John F. DiJoseph,Gisela Mir	3

About John F. DiJoseph

John F. DiJoseph is a scholar working on Oncology, Cancer Research and Gastroenterology, having authored 45 papers that have together received 1.5k indexed citations. Recurring topics across this work include Protease and Inhibitor Mechanisms (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Peptidase Inhibition and Analysis (9 papers). The work is most often cited by research in Transplantation (103 citations), Oncology (739 citations) and Radiology, Nuclear Medicine and Imaging (459 citations). John F. DiJoseph has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Maureen Dougher, Nitin K. Damle, Douglas Armellino, Erwin R. Boghaert, Philip R. Hamann, Arthur Kunz, Kiran Khandke, Gisela Mir, Justin Moran and Latha Sridharan. Their work appears in journals such as Blood, Gastroenterology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact